TY - JOUR
T1 - Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer
AU - Umemoto, M.
AU - Yokoyama, Y.
AU - Sato, S.
AU - Tsuchida, S.
AU - Al-Mulla, F.
AU - Saito, Y.
N1 - Funding Information:
This study was supported in part by the Karoji Memorial Fund of the Hirosaki University School of Medicine, by a Grant-in Aid for Cancer Research (No. 12770893) from the Ministry of Education, Science and Culture of Japan, and by a grant from Kuwait Foundation for the Advancement of Sciences number 990707.
PY - 2001/9/28
Y1 - 2001/9/28
N2 - We have recently reported a novel function for carbonyl reductase (CR), namely, its ability to modulate the metastatic potential of malignant mouse cells. Because there are currently no data addressing a similar function for CR in human cancers, the aim of this study was to assess a correlation between survival and metastasis, and CR level in epithelial ovarian cancer. Using anti-CR antibody, immunohistochemical staining was performed on 73 epithelial ovarian cancers, 13 borderline malignant tumours, and 25 benign ovarian tumours for a total of 111 specimens. The combined rate for strongly and weakly positive reactions for CR was 32.0% for benign tumours, 38.5% for borderline malignant tumours, and 61.6% for ovarian cancers. The CR-positive rate was 35.7% (weakly positive alone) for ovarian cancers with retroperitoneal lymph node (RLN) metastasis and 67.8% for those without RLN metastasis (P < 0.05). The 5-year survival rate was 62.7% for the patients with CR-negative cancer and 86.1% for those with CR-positive cancer (P < 0.05). The present results indicate that decreased CR expression in epithelial ovarian cancer is associated with RLN metastasis and poor survival.
AB - We have recently reported a novel function for carbonyl reductase (CR), namely, its ability to modulate the metastatic potential of malignant mouse cells. Because there are currently no data addressing a similar function for CR in human cancers, the aim of this study was to assess a correlation between survival and metastasis, and CR level in epithelial ovarian cancer. Using anti-CR antibody, immunohistochemical staining was performed on 73 epithelial ovarian cancers, 13 borderline malignant tumours, and 25 benign ovarian tumours for a total of 111 specimens. The combined rate for strongly and weakly positive reactions for CR was 32.0% for benign tumours, 38.5% for borderline malignant tumours, and 61.6% for ovarian cancers. The CR-positive rate was 35.7% (weakly positive alone) for ovarian cancers with retroperitoneal lymph node (RLN) metastasis and 67.8% for those without RLN metastasis (P < 0.05). The 5-year survival rate was 62.7% for the patients with CR-negative cancer and 86.1% for those with CR-positive cancer (P < 0.05). The present results indicate that decreased CR expression in epithelial ovarian cancer is associated with RLN metastasis and poor survival.
KW - Carbonyl reductase
KW - Epithelial ovarian cancer
KW - Lymph node metastasis
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=0035964625&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6692034
DO - 10.1038/sj.bjc.6692034
M3 - Article
C2 - 11592776
AN - SCOPUS:0035964625
SN - 0007-0920
VL - 85
SP - 1032
EP - 1036
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 7
ER -
